Company news
Ardelyx, Inc. news in 2023
Ardelyx, Inc.'s news releases, calls and decks from 2023, newest first.
Ardelyx to Participate at the Piper Sandler 35th Annual Healthcare Conference
November 20, 2023
XPHOZAH® (tenapanor) Granted Orphan Drug Designation by U.S. FDA for the Treatment of Pediatric Hyperphosphatemia
November 14, 2023
Ardelyx Announces Departure of Board Member
November 12, 2023
Ardelyx to Participate at the Jefferies London Healthcare Conference
November 9, 2023
Ardelyx Announces XPHOZAH® (tenapanor) Now Available in the United States
November 5, 2023
Ardelyx Shares Positive Data from Studies of XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor, at ASN Kidney Week 2023
November 2, 2023
Ardelyx Reports Third Quarter 2023 Financial Results and Updates 2023 U.S. IBSRELA® Net Sales Revenue Guidance
October 30, 2023
Ardelyx Shares Positive Data on Symptom Response During Treatment With IBSRELA® (tenapanor) for IBS-C and hosts IBS-C Product Theater at ACG 2023
October 22, 2023
Ardelyx to Report Third Quarter 2023 Financial Results on October 31, 2023
October 17, 2023
FDA Approves XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor
October 16, 2023
Ardelyx Announces Amendment of Debt Financing Agreement with SLR Capital Partners to Provide $50 Million of Additional Committed Capital
October 16, 2023
Ardelyx to Present Data Updates for XPHOZAH (tenapanor) for Hyperphosphatemia at Kidney Week 2023 November 1-5 in Philadelphia, PA
October 12, 2023
Ardelyx Shares Preliminary Data on Use of IBSRELA® (tenapanor) in Pediatric IBS-C Patients at NASPGHAN 2023
October 3, 2023
Ardelyx Announces Publication of Positive Results from T3MPO-3 Long-Term Open-Label Safety Trial of Tenapanor for IBS-C in the Journal of Neurogastroenterology and Motility
September 27, 2023
Tenapanor for Hyperphosphatemia Approved in Japan
September 24, 2023
Ardelyx Showcased Encouraging Data on Treatment Satisfaction and Efficacy of IBSRELA® (tenapanor) for IBS-C at GHAPP 2023
September 10, 2023
Ardelyx to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 7, 2023
Ardelyx Reports Second Quarter 2023 Financial Results and Provides 2023 IBSRELA Net Sales Revenue Guidance
August 1, 2023
Ardelyx to Report Second Quarter 2023 Financial Results on August 2, 2023
July 25, 2023
Ardelyx to Present at the H.C. Wainwright 2nd Annual Kidney Conference
July 19, 2023
Ardelyx Announces Acceptance of New Drug Application for Tenapanor for Hyperphosphatemia in China
July 12, 2023
Leading Proxy Advisory Firms ISS and Glass Lewis Recommend Ardelyx Stockholders Vote in Favor of Proposed Share Increase
June 4, 2023
Ardelyx to Present at the Jefferies 2023 Healthcare Conference
May 30, 2023
Ardelyx Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH® (tenapanor)
May 16, 2023
Ardelyx Presents Positive Data at DDW 2023 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
May 8, 2023
Ardelyx Reports First Quarter 2023 Financial Results and Provides Business Update
May 2, 2023
Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week Conference
April 30, 2023
Ardelyx to Report First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023
April 25, 2023
Ardelyx Resubmits New Drug Application to U.S. Food and Drug Administration for XPHOZAH® (tenapanor)
April 17, 2023
Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2023 Spring Clinical Meetings
April 11, 2023
Ardelyx Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 1, 2023
Ardelyx Publishes First Environmental, Social and Governance (ESG) Report
February 27, 2023
Ardelyx to Participate at the Cowen 43rd Annual Health Care Conference
February 26, 2023
Ardelyx to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 2, 2023
February 22, 2023